|By PR Newswire||
|August 26, 2013 09:09 AM EDT||
NEW YORK, Aug. 26, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
This drug pipeline update covers a wide array of biological drugs, such as: antibodies,proteins, peptides, DNA, RNA and cellular therapies.
There are today 881 companies plus partners developing 1527 biological drugs in 3359 developmental projects in cancer. In addition, there are 24 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 889 drugs. Biologicals In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 604 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 566 out of the 570 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 82 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.
How May Drug Pipeline Update Be of Use?* Show investors/board/management that you are right on top of drug development progress in your therapeutic area. * Find competitors, collaborations partners, M&A candidates etc. * Jump start competitive drug intelligence operations * Excellent starting point for world wide benchmarking * Compare portfolio and therapy focus with your peers * Speed up pro-active in-/out licensing strategy work * Fast and easy way of tracking drugs using search engines; just one click from inside the application and you may search the World Wide Web and PubMed for any drug. Drug Pipeline Update is delivered to you as a downloadable application, which requires no installation on your computer. Please read more about application features and system requirements below.Drug Pipeline Update at a Glance
InvestigatorsIncludes more than 881 principal companies plus their collaborators. There is direct access from inside the application to web pages of all principal companies.
Note: You are able to sort and find drugs according to companies and partners from drop-down menus in the application. You may also sort and find drugs according to country of companies.
Drug name & SynonymsLists commercial, generic and code names for drugs.
This Drug Pipeline Update contains 1527 biological drugs in development, which have a total of 3359 developmental projects in cancer. In addition there are suspended and ceased drugs.
Pipeline Breakdown According to Number of Drugs
Phase III# 109
Phase II# 371
Phase I# 405
No Data# 12
Note: You are able to sort and find drugs according to developmental stage from drop-down menu in the application.
Included biological drugs are also in development for 337 other indications, where of 115 are different cancer indications.
Note: You are able to find and sort drugs according to type of indication from drop-down menu in the application.
TargetsMutationsAll targets are cross-referenced with the Catalogue of Somatic Mutations in Cancer (COSMIC). It is designed to store and display somatic mutation information and related details and contains information relating to human cancers. To date 566 out of the 570 studied drug targets so far have been recorded with somatic mutations and the software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information.
The identity of available biological structures on 349 drug targets was retrieved from the RCSB Protein Databank for you to easily review the 4087 structures available today among drug targets.
Identified drugs are linked to more than 604 different targets, divided into 82 classifications of molecular function:- Acid phosphatase activity- Antigen binding- ATPase activity- Auxiliary transport protein activity- B cell receptor activity- Binding- Carboxy-lyase activity- Carboxypeptidase activity- Catalytic activity- Cell adhesion molecule activity- Chaperone activity- Chemokine activity- Cofactor binding- Complement activity- Cysteine-type peptidase activity- Cytokine activity- Cytoskeletal protein binding- Deaminase activity- Defense/immunity protein activity- DNA binding- DNA repair protein- DNA topoisomerase activity- DNA-directed DNA polymerase activity- DNA-directed RNA polymerase activity- DNA-methyltransferase activity- Extracellular ligand-gated ion channel activity- Extracellular matrix structural constituent- Fucosyltransferase activity- G-protein coupled receptor activity- Growth factor activity- Growth factor binding- GTPase activator activity- GTPase activity- Guanylate cyclase activity- Heat shock protein activity- Hormone activity- Hydrolase activity- Intracellular ligand-gated ion channel activity- Isomerase activity- Kinase activity- Kinase binding- Kinase regulator activity- Ligand-dependent nuclear receptor activity- Ligase activity- Lipid kinase activity- Lipid phosphatase activity- Metallopeptidase activity- MHC class I receptor activity- Molecular function unknown- Motor activity- Oxidoreductase activity- Peptidase activity- Peptide hormone- Peroxidase activity- Protease inhibitor activity- Protein binding- Protein serine/threonine kinase activity- Protein threonine/tyrosine kinase activity- Protein tyrosine/serine/threonine phosphatase activity- Protein-tyrosine kinase activity- Receptor activity- Receptor binding- Receptor signaling complex scaffold activity- Receptor signaling protein serine/threonine kinase activity- Receptor signaling protein tyrosine phosphatase activity- RNA binding- RNA-directed DNA polymerase activity- Serine-type peptidase activity- Signal transducer activity- Structural constituent of cytoskeleton- Structural molecule activity- Superoxide dismutase activity- T cell receptor activity- Transcription factor activity- Transcription regulator activity- Transferase activity- Translation regulator activity- Transmembrane receptor activity- Transmembrane receptor protein tyrosine kinase activity- Transporter activity- Ubiquitin-specific protease activity- Unclassified
Identified targets are categorized into 38 different primary and alternate sub-cellular localizations:
- Apical membrane
- Cell junction
- Cell surface
- Clathrin-coated vesicle
- Cytoplasmic vesicle
- Early endosome
- Endoplasmic reticulum
- Extracellular matrix
- Golgi apparatus
- Golgi membrane
- Immunological synapse
- Integral to membrane
- Late endosome
- Membrane fraction
- Mitochondrial matrix
- Mitochondrial membrane
- Perinuclear region
- Perinuclear vesicle
- Peroxisomal matrix
- Plasma membrane
- Sarcoplasmic reticulum
- Secretory granule
- Secretory vesicle
- Soluble fraction
Note: You are able to find and sort drugs according to target gene name, protein name, molecular function of target, target localization, presence of mutations and availability of biological structures of target from drop-down menus in the application.
Target Expression Profile
Direct links are provided from inside the application to 716 protein expression profiles of 470 drug targets in various human tissues and cancer types, cell lines and primary cells, including up to:
- 48 different normal tissue types
- 20 different types of cancer
- 47 cell lines
- 12 samples of primary blood cells
Pathway ReferalsIdentified targets have been cross referenced against their involvement in different cellular pathways, according to BioCarta, KEGG, NCI-Nature and NetPath.- BioCarta# 265 Pathways- KEGG# 194 Pathways- NCI-Nature# 251 Pathways- NetPath# 32 Pathways
Note: You are able to find and sort drugs according to targeted pathways from drop-down menus in the application.
MechanismIn total there are different drug mechanism of action represented in this Drug Pipeline Update.
Note: You are able to find and sort drugs according to mechanism of action from drop-down menu in the application.
CompoundIdentified drug compounds are described by:
Compound type, Chemical name, CAS Number and molecular weight
Note: You are able to sort and find drugs according to compound type from drop-down menu in the application.
Progress analysis and review of drug development. A typical drug profile reports on, depending on stage of development and available information:
Drug Name & SynonymsPresentation of drug name and synonyms
Principal Company & Partners
Presentation of principal company and partners
Target and Molecular Function of TargetDescribed target(s) is/are presented with:Official Gene Symbol – Chromosome Location – Gene & Protein Name – Molecular Function
Described target(s) is/are presented with primary and alternate localizations.
Target Expression Profiles
Links to protein expression profile(s) of target(s) in various human tissues, cell lines and primary cells, including up to:
48 different normal tissue types
20 different types of cancer
47 cell lines
12 samples of primary blood cells
MutationAll targets are cross-referenced with the Catalogue of Somatic Mutations in Cancer (COSMIC). It is designed to store and display somatic mutation information and related details and contains information relating to human cancers.
The identity of available biological structures on drug targets was retrieved from the RCSB Protein Databank for you to easily review what available structures of drug targets exist.
Targeted PathwaysDescribed target(s) is/are matched for the involvement in cellular pathways according to BioCarta, KEGG, NCI-Nature and NetPath.
Drug mechanism of action
Developmental ProjectsSummary field of developmental projects for the drug, including indication, developmental stage and status.Example:Cancer, myeloma – Phase II Clinical Trial – ActiveCancer, prostate – Phase III Clinical Trial – Ceased
Short introduction to drug
Compound DataCompound type, Chemical name, CAS Number and molecular weight
Available patent information related to the drug is presented here.
Fillings and ApprovalsApprovals and submissionsAnalyst comments
Deals & Licensing
Collaborations and deals
Availability for licensing
Phase IV DataAvailable Phase IV development data, developmental history and scientific data.
Phase III Data
Available Phase III development data, developmental history and scientific data.
Phase II DataAvailable Phase II development data, developmental history and scientific data.
Phase I Data
Available Phase I development data, developmental history and scientific data.
Phase 0 DataAvailable Phase 0 development data, developmental history and scientific data.
Available preclinical development data, developmental history and scientific data.
Discovery DataAvailable discovery development data, developmental history and scientific data.
Search, Find and Filter Panel with Initial Result Presentation
With this panel you can define your selectivity in each drug search with up to 24 different drug specific parameters. Each parameter has multi-select options to them and can be used as either an inclusion parameter or exclusion parameter.
The initial result table is a dynamic sortable table which gives you a fast overview of found results and can be narrowed down further by your own additional keywords.
Direct linkage from inside the application to related internet resources
- Drug data is linked to search engines like Google and PubMed
- Drug target data is linked directly to BioCarta, Human Protein Atlas, KEGG, NCI-Nature, NetPath etc.
- Direct links to company web pages of companies
Dynamic Report GeneratorOur dynamic report generator lets you with ease and speed generate html reports directly in your web browser (Internet Explorer and FireFox), whether it is a single drug profile or an entire search you want have a report of.
System Requirements- Operating system: Windows (2000/XP/Vista/7) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)- Browser Application (Internet Explorer)- Internet access (to access related internet resources)
Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001
Complete Internet of Things (IoT) embedded device security is not just about the device but involves the entire product’s identity, data and control integrity, and services traversing the cloud. A device can no longer be looked at as an island; it is a part of a system. In fact, given the cross-domain interactions enabled by IoT it could be a part of many systems. Also, depending on where the device is deployed, for example, in the office building versus a factory floor or oil field, security ha...
Sep. 27, 2016 04:45 PM EDT Reads: 314
More and more companies are looking to microservices as an architectural pattern for breaking apart applications into more manageable pieces so that agile teams can deliver new features quicker and more effectively. What this pattern has done more than anything to date is spark organizational transformations, setting the foundation for future application development. In practice, however, there are a number of considerations to make that go beyond simply “build, ship, and run,” which changes ho...
Sep. 27, 2016 04:00 PM EDT Reads: 2,627
SYS-CON Events announced today that Niagara Networks will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Niagara Networks offers the highest port-density systems, and the most complete Next-Generation Network Visibility systems including Network Packet Brokers, Bypass Switches, and Network TAPs.
Sep. 27, 2016 03:30 PM EDT Reads: 281
SYS-CON Events announced today that eCube Systems, a leading provider of middleware modernization, integration, and management solutions, will exhibit at @DevOpsSummit at 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. eCube Systems offers a family of middleware evolution products and services that maximize return on technology investment by leveraging existing technical equity to meet evolving business needs. ...
Sep. 27, 2016 03:15 PM EDT Reads: 1,357
SYS-CON Events announced today that Commvault, a global leader in enterprise data protection and information management, has been named “Bronze Sponsor” of SYS-CON's 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Commvault is a leading provider of data protection and information management solutions, helping companies worldwide activate their data to drive more value and business insight and to transform moder...
Sep. 27, 2016 03:15 PM EDT Reads: 2,756
Using new techniques of information modeling, indexing, and processing, new cloud-based systems can support cloud-based workloads previously not possible for high-throughput insurance, banking, and case-based applications. In his session at 18th Cloud Expo, John Newton, CTO, Founder and Chairman of Alfresco, described how to scale cloud-based content management repositories to store, manage, and retrieve billions of documents and related information with fast and linear scalability. He addres...
Sep. 27, 2016 03:15 PM EDT Reads: 2,851
The many IoT deployments around the world are busy integrating smart devices and sensors into their enterprise IT infrastructures. Yet all of this technology – and there are an amazing number of choices – is of no use without the software to gather, communicate, and analyze the new data flows. Without software, there is no IT. In this power panel at @ThingsExpo, moderated by Conference Chair Roger Strukhoff, panelists will look at the protocols that communicate data and the emerging data analy...
Sep. 27, 2016 03:00 PM EDT Reads: 1,689
Fifty billion connected devices and still no winning protocols standards. HTTP, WebSockets, MQTT, and CoAP seem to be leading in the IoT protocol race at the moment but many more protocols are getting introduced on a regular basis. Each protocol has its pros and cons depending on the nature of the communications. Does there really need to be only one protocol to rule them all? Of course not. In his session at @ThingsExpo, Chris Matthieu, co-founder and CTO of Octoblu, walk you through how Oct...
Sep. 27, 2016 02:45 PM EDT Reads: 2,201
We’ve been doing it for years, decades for some. How many websites have you created accounts on? Your bank, your credit card companies, social media sites, hotels and travel sites, online shopping sites, and that’s just the start. We do it often without even thinking about it, quickly entering our personal information, our data, in a plethora of systems. Sometimes we’re not even aware of the information we are providing. It could be very personal information (think of the security questions you ...
Sep. 27, 2016 02:45 PM EDT Reads: 4,633
Digital innovation is the next big wave of business transformation based on digital technologies of which IoT and Big Data are key components, For example: Business boundary innovation is a challenge to excavate third-party business value using IoT and BigData, like Nest Business structure innovation may propose re-building business structure from scratch, as Uber does in the taxicab industry The social model innovation is also a big challenge to the new social architecture with the design fr...
Sep. 27, 2016 02:45 PM EDT Reads: 1,252
Is your aging software platform suffering from technical debt while the market changes and demands new solutions at a faster clip? It’s a bold move, but you might consider walking away from your core platform and starting fresh. ReadyTalk did exactly that. In his General Session at 19th Cloud Expo, Michael Chambliss, Head of Engineering at ReadyTalk, will discuss why and how ReadyTalk diverted from healthy revenue and over a decade of audio conferencing product development to start an innovati...
Sep. 27, 2016 02:15 PM EDT Reads: 1,989
All clouds are not equal. To succeed in a DevOps context, organizations should plan to develop/deploy apps across a choice of on-premise and public clouds simultaneously depending on the business needs. This is where the concept of the Lean Cloud comes in - resting on the idea that you often need to relocate your app modules over their life cycles for both innovation and operational efficiency in the cloud. In his session at @DevOpsSummit at19th Cloud Expo, Valentin (Val) Bercovici, CTO of So...
Sep. 27, 2016 02:00 PM EDT Reads: 1,443
Data is an unusual currency; it is not restricted by the same transactional limitations as money or people. In fact, the more that you leverage your data across multiple business use cases, the more valuable it becomes to the organization. And the same can be said about the organization’s analytics. In his session at 19th Cloud Expo, Bill Schmarzo, CTO for the Big Data Practice at EMC, will introduce a methodology for capturing, enriching and sharing data (and analytics) across the organizati...
Sep. 27, 2016 01:30 PM EDT Reads: 1,713
SYS-CON Events announced today that Tintri Inc., a leading producer of VM-aware storage (VAS) for virtualization and cloud environments, will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Tintri VM-aware storage is the simplest for virtualized applications and cloud. Organizations including GE, Toyota, United Healthcare, NASA and 6 of the Fortune 15 have said “No to LUNs.” With Tintri they mana...
Sep. 27, 2016 01:00 PM EDT Reads: 2,816
There is little doubt that Big Data solutions will have an increasing role in the Enterprise IT mainstream over time. Big Data at Cloud Expo - to be held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA - has announced its Call for Papers is open. Cloud computing is being adopted in one form or another by 94% of enterprises today. Tens of billions of new devices are being connected to The Internet of Things. And Big Data is driving this bus. An exponential increase is...
Sep. 27, 2016 01:00 PM EDT Reads: 2,661